(Q38239285)

31 August 2017

title

FcγRIIB as a key determinant of agonistic antibody efficacy (English)

1 reference

31 August 2017

3

1 reference

31 August 2017

Ann L White

1

1 reference

31 August 2017

Stephen A Beers

series ordinal

2

1 reference

31 August 2017

publication date

1 January 2014

1 reference

Current Topics in Microbiology and Immunology

31 August 2017

published in

1 reference

31 August 2017

volume

382

1 reference

31 August 2017

page(s)

355-372

1 reference

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Long-Term Human B Cell Lines Dependent on Interleukin-4 and antibody to CD40

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

SHIP modulates immune receptor responses by regulating membrane association of Btk.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The biology of CD20 and its potential as a target for mAb therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Negative signaling in Fc receptor complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The same tyrosine-based inhibition motif, in the intra-cytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Enhancement of T cell-independent immune responses in vivo by CD40 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The role of the CD40 pathway in the pathogenesis and treatment of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Dominant expression of the inhibitory FcgammaRIIB prevents antigen presentation by murine plasmacytoid dendritic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Mutational analysis reveals multiple distinct sites within Fc gamma receptor IIB that function in inhibitory signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The TRAIL to selective tumor death

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Isolation and characterization of human tonsil dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Anti-CD20 monoclonal antibodies: historical and future perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Mechanism of antigen-driven selection in germinal centres

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Erratum: A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Antibodies, Fc receptors and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fc-receptors as regulators of immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fcgamma receptors: old friends and new family members

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: analysis of early and late activation events

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The functional variant of the inhibitory Fcγ receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The future of antibodies as cancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Isolated human follicular dendritic cells display a unique antigenic phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Agonistic CD40 antibodies and cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Immunotherapy Targeting Inhibitory Fc Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07911-0_16

10.1007/978-3-319-07911-0_16

31 March 2020

Identifiers

DOI

1 reference

31 August 2017

1 reference